WAVEMAN · COMPANY

PFSA · Profusa, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

PFSA

Name: Profusa, Inc. (PFSA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Profusa, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001859807

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

-$116.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

CONVERSIONS · 180D

codes C/M, not in net · $2.6M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$116.3K over 180 days

-$116.3K over 90 days · -$116.3K of it by a 10%+ holder

more than 59% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

6 funds added or opened last quarter

below 94% of Medical Devices

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

$6.5M repurchased, FY to 2025-06-30

below 71% of Medical Devices

SHORT

9.9% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

more than 88% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

NorthView Sponsor I, LLC disclosed a 5%+ stake (49.9%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -99.6%

-99.6%12M

INSIDER BUYINSIDER SELL13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows a net $116.3K sold by insiders over 180 days, 6 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Profusa, Inc. insiders sold a net $116.3K of stock across 14 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

HRT FINANCIAL LP

—

SELL

2026-08-17

18,395.0

$109.3K

HRT FINANCIAL LP

—

SELL

2026-08-14

3,163.0

$2.9K

HRT FINANCIAL LP

—

SELL

2026-08-13

42,411.0

$37.7K

HRT FINANCIAL LP

—

BUY

2026-08-12

5,585.0

$5.4K

HRT FINANCIAL LP

—

SELL

2026-08-11

2,280.0

$2.2K

14 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 9 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

StoneX Group Inc.

16,879.0 sh

$6.0K

GEODE CAPITAL MANAGEMENT, LLC

16,417.0 sh

$1.9K

VANGUARD CAPITAL MANAGEMENT LLC

3,939.0 sh

$457

Tower Research Capital LLC (TRC)

3,761.0 sh

$438

IFP Advisors, Inc

3,000.0 sh

$350

5%+ owners

13D = intent to influence · 13G = passive

NorthView Sponsor I, LLC

ACTIVIST 13D · 2026-08-19

49.9%

Jack Stover

ACTIVIST 13D · 2026-08-19

49.9%

Fred Knechtel

ACTIVIST 13D · 2026-08-19

49.9%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$1.5K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$2.0K POSITION · AS OF 2026-03-31

0.0%

Fidelity Nasdaq Composite Index Fund

$219 POSITION · AS OF 2026-02-28

0.0%

Fidelity Series Total Market Index Fund

$226 POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	—	$100.0K	—	—
OPERATING INCOME	$-27.7M	$-4.5M	$-1.5M	$-1.3M
NET INCOME	$-35.8M	$-9.2M	$1.2M	$7.2M
EPS (DILUTED)	-107.01	-357.14	0.12	0.30
OPERATING CASH FLOW	$-16.2M	$-2.1M	$-2.1M	$-581.2K
CASH	$1.8M	$191.0K	$4.5K	$193.5K
BUYBACKS	—	$3.2M	$184.8M	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE